Monitoring ctDNA Predicts HER2+ Cancer Treatment Response Monitoring ctDNA Predicts HER2+ Cancer Treatment Response

Tracking a patient ' s circulating tumor DNA (ctDNA) can offer insight into how well-targeted therapies work in the early stages of treatment for HER2-positive cancers.MDedge News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news